{Reference Type}: Journal Article
{Title}: A computational framework to improve cross-platform implementation of transcriptomics signatures.
{Author}: Kreitmann L;D'Souza G;Miglietta L;Vito O;Jackson HR;Habgood-Coote D;Levin M;Holmes A;Kaforou M;Rodriguez-Manzano J;
{Journal}: EBioMedicine
{Volume}: 105
{Issue}: 0
{Year}: 2024 Jul 19
{Factor}: 11.205
{DOI}: 10.1016/j.ebiom.2024.105204
{Abstract}: The emergence of next-generation sequencing technologies and computational advances have expanded our understanding of gene expression regulation (i.e., the transcriptome). This has also led to an increased interest in using transcriptomic biomarkers to improve disease diagnosis and stratification, to assess prognosis and predict the response to treatment. Significant progress in identifying transcriptomic signatures for various clinical needs has been made, with large discovery studies accounting for challenges such as patient variability, unwanted batch effects, and data complexities; however, obstacles related to the technical aspects of cross-platform implementation still hinder the successful integration of transcriptomic technologies into standard diagnostic workflows. In this article, we discuss the challenges associated with integrating transcriptomic signatures derived using high-throughput technologies (such as RNA-sequencing) into clinical diagnostic tools using nucleic acid amplification (NAA) techniques. The novelty of the proposed approach lies in our aim to embed constraints related to cross-platform implementation in the process of signature discovery. These constraints could include technical limitations of amplification platform and chemistry, the maximal number of targets imposed by the chosen multiplexing strategy, and the genomic context of identified RNA biomarkers. Finally, we propose to build a computational framework that would integrate these constraints in combination with existing statistical and machine learning models used for signature identification. We envision that this could accelerate the integration of RNA signatures discovered by high-throughput technologies into NAA-based approaches suitable for clinical applications.